CN113383961A - Composition containing NMN and citrulline and preparation method thereof - Google Patents

Composition containing NMN and citrulline and preparation method thereof Download PDF

Info

Publication number
CN113383961A
CN113383961A CN202110397441.XA CN202110397441A CN113383961A CN 113383961 A CN113383961 A CN 113383961A CN 202110397441 A CN202110397441 A CN 202110397441A CN 113383961 A CN113383961 A CN 113383961A
Authority
CN
China
Prior art keywords
parts
citrulline
nmn
biotin
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110397441.XA
Other languages
Chinese (zh)
Inventor
李桂东
王剑锋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Lingxi Health Technology Co ltd
Original Assignee
Hangzhou Lingxi Health Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Lingxi Health Technology Co ltd filed Critical Hangzhou Lingxi Health Technology Co ltd
Priority to CN202110397441.XA priority Critical patent/CN113383961A/en
Publication of CN113383961A publication Critical patent/CN113383961A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a composition containing NMN and citrulline and a preparation method thereof. The feed is prepared from the following raw materials in parts by weight: NMN: 100-300 parts; citrulline: 1-100 parts; arginine: 1-100 parts; 1-10 parts of biotin; and 1-10 parts of magnesium glycinate. The formula adopts NMN as a main raw material, and citrulline, arginine, biotin and magnesium glycinate are compounded and used, and the method comprises the following steps: drying and crushing the raw materials, sieving the raw materials by a 30-80-mesh sieve to obtain uniform raw material particles, weighing the raw materials according to the weight part ratio, mixing the weighed raw materials and uniformly stirring to obtain the powder composition. According to the invention, the mixed preparation is prepared from citrulline, arginine, biotin and magnesium glycinate and NMN, so that the fatigue state of people can be effectively improved, and the anti-aging effects of protecting vascular endothelium, improving complexion and the like are achieved.

Description

Composition containing NMN and citrulline and preparation method thereof
The technical field is as follows:
the invention belongs to the technical field of dietary supplements and nutriments, and particularly relates to a composition of citrulline and NMN and a preparation method thereof.
Background
Citrulline, also known as carbamoylornithine, is a white crystal in pure form. Citrulline is a non-protein alpha-amino acid with the ability to form peptide bonds, but is not involved in protein synthesis. Foreign scientists have made more research on citrulline, especially in japan, the united states and europe. CN201610844840.5 describes the physiological function of citrulline: foreign scientists have studied that citrulline has some very important pharmacological functions, such as free radical scavenging action, and has very important significance in the health care aspect of human body: vasodilatation, which is expected to become a good medicine for treating endotoxemia and toxemia. In recent years, many foreign researches show that citrulline has many important physiological functions, such as free radical removal, foreign body rejection effect indicators, vasodilation, blood pressure stabilization, rheumatoid arthritis diagnosis, oxidation resistance and the like, and has very wide application prospects.
NMN is short for beta-Nicotinamide mononucleotide (Nicotinamide mononucleotide), and is a precursor of a Nicotinamide adenine dinucleotide (NAD +) salvage synthesis pathway in mammals. NMN has the functions of repairing mitochondrial defects, protecting heart, improving pancreatic islet function, repairing brain injury and the like. NMN can significantly improve age-related physiological decline, such as inhibiting age-related weight gain, enhancing energy metabolism, improving insulin sensitivity and lipid profile in plasma, and improving vascular function. Patent document CN202010610059.8 reports a solid beverage containing NMN, bovine colostrum, L-lysine and the like with the functions of restoring human cell vitality and resisting aging; patent document CN201911296257.5 reports an antioxidant nutritional composition capsule containing NMN, coenzyme Q10, vitamin E, etc.; patent document CN201910641532.6 reports a composition containing nicotinamide mononucleotide and ice-leaf sunflowers; patent document CN202010243588.9 reports a microcapsule preparation containing nicotinamide mononucleotide and a blue extract; pharmaceutical compositions such as transdermal patches, capsules, microcapsules, sustained-release pellets, sustained-release enteric orally disintegrating tablets and the like containing NMN are reported in patent documents CN202010561048.5, CN202010811659.0, CN202011041891.7, CN202011044214.0 and CN202011041898.9, respectively.
With the rapid development of social economy, the pressure of people is gradually increased, and especially, the life habits such as irregular diet and night-out and the like cause the increase of sub-health states such as fatigue, bad complexion, cardiovascular function reduction, premature senility and the like. Citrulline and NMN are derived from various foods in daily life, but in lower amounts. In the prior art, relevant documents and patents for compounding NMN and citrulline to supplement the requirements of human bodies are not found. The inventor unexpectedly discovers that the synergistic effect of citrulline and NMN can be used for improving fatigue state, enhancing blood vessel function and delaying aging speed through long-term experimental research, and the effect and the stability are good.
The invention content is as follows:
the invention aims to provide a composition containing NMN and citrulline and a preparation method thereof, so as to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme:
a composition containing NMN and citrulline comprises the following raw materials in parts by weight:
NMN: 100-300 parts;
citrulline: 1-100 parts;
l-arginine: 1-100 parts;
1-10 parts of biotin;
and 1-10 parts of magnesium glycinate.
The invention adopts NMN as the main material, and citrulline, L-arginine, biotin and magnesium glycinate are compounded and used, the formula is reasonable, and the invention has the characteristics of resisting fatigue, improving vascular endothelium and delaying senility.
Preferably, the feed consists of the following raw materials in parts by weight:
NMN: 120-280 parts;
citrulline: 10-90 parts;
arginine: 10-90 parts;
biotin: 2-9 parts of a solvent;
and 2-9 parts of magnesium glycinate.
Preferably, the feed consists of the following raw materials in parts by weight:
NMN: 140-260 parts;
citrulline: 20-80 parts;
arginine: 20-80 parts;
3-8 parts of biotin;
3-8 parts of magnesium glycinate.
Preferably, the feed consists of the following raw materials in parts by weight:
NMN: 150-250 parts;
citrulline: 30-70 parts;
arginine: 30-70 parts;
biotin: 4-6 parts;
magnesium glycinate: 4-6 parts.
As a further scheme of the invention: the purity of NMN is greater than or equal to 99%, the purity of citrulline is greater than or equal to 98%, the purity of L-arginine is greater than or equal to 99%, the purity of biotin is greater than or equal to 98%, and the purity of magnesium glycinate is greater than or equal to 98%.
As a still further scheme of the present invention, the auxiliary materials further include at least one of the following auxiliary materials in parts by weight: zinc gluconate, vitamin B6, pyrro-quinoline, betaine and resistant dextrin.
The invention provides a preparation method of a composition containing NMN and citrulline, which comprises the following steps:
s1: sieving, namely sieving the raw materials by a 30-80-mesh sieve, and controlling the particle size in a proper range so that the raw materials are mixed more easily and uniformly;
s2: weighing, namely weighing citrulline, NMN, L-arginine, biotin and magnesium glycinate from the raw materials prepared in the step S1 according to the mass parts of the formula;
s3: premixing, namely putting NMN, citrulline and L-arginine into a mixing tank, stirring and mixing to obtain a first mixed material, and putting biotin and magnesium glycinate into another mixing tank, stirring and mixing to obtain a second mixed material;
s4: mixing, namely putting the first uniform mixture, the second uniform mixture and the auxiliary materials in the step S3 into another mixing tank, and uniformly stirring to obtain a powdery mixture;
s5: and (5) subpackaging and filling, namely canning and sealing the uniform powdery mixture obtained in the step S4 in a sterile environment, and preparing powder.
Preferably, the stirring temperature in S3 is 30-40 ℃.
In summary, the invention has the following beneficial effects:
(1) NMN is used as a main raw material, when the NMN level in a body is increased, the usability of NAD + is increased immediately, the Oxygen Consumption Rate (OCR) of mitochondria is increased, the fusion of the mitochondria is promoted, the fission trend is reduced, and the mitochondria generate longer mitochondria in a hippocampal subregion, so that the respiratory function of the mitochondria is enhanced, and the fatigue state is improved; citrulline acts synergistically with NMN to help the body overcome fatigue and stress, promote energy metabolism and improve vascular function. L-arginine is essential amino acid for human body, and can improve male sexual dysfunction and cardiovascular related diseases, increase insulin secretion and reduce diabetes related complications; biotin, also known as vitamin H, is a water-soluble vitamin, and has the functions of enhancing the immune response and resistance of the organism, maintaining the integrity and the soundness of epithelial tissue structure and the like; magnesium glycinate is the best absorption form of magnesium and can help the body to maintain proper magnesium levels.
(2) The anti-aging experiment and the anti-fatigue experiment show that the composition has the effects of resisting aging and fatigue and enhancing physiological functions.
(3) The invention provides a preparation method of an anti-fatigue and anti-aging functional food, which is simple to operate and suitable for large-scale production.
The specific implementation mode is as follows:
the technical solution of the present patent will be further described in detail with reference to the following embodiments.
In the examples and comparative examples, the purity of NMN is greater than or equal to 99%, the purity of citrulline is greater than or equal to 98%, the purity of L-arginine is greater than or equal to 99%, the purity of biotin is greater than or equal to 98%, and the purity of magnesium glycinate is greater than or equal to 98%.
Example 1
The embodiment provides a formula and a preparation method of a citrulline and NMN preparation, wherein the components and the corresponding parts by weight are shown in Table 1 and are prepared by the following steps:
(1) sieving: sieving each raw material component by a 50-mesh sieve for later use;
(2) weighing: weighing the raw materials in turn according to the formula dosage in table 1;
(3) premixing: at the temperature of 30-40 ℃, putting NMN, citrulline and L-arginine into a mixing tank, stirring and mixing to obtain a first mixed material, putting biotin and magnesium glycinate into another mixing tank, stirring and mixing to obtain a second mixed material;
(4) mixing: putting the first mixed material, the second mixed material and the auxiliary material resistant dextrin in the step (3) into another mixing tank, and uniformly stirring to obtain a mixture;
(5) subpackaging and filling: and (4) canning and sealing the uniform mixture in the step (4) in a sterile environment.
Examples 2 to 7
The difference between a formula of a citrulline and NMN preparation and a preparation method thereof and the embodiment 1 is that the components and the corresponding parts by weight are shown in the table 1.
TABLE 1 Components and parts by weight of examples 1-7
Figure RE-GDA0003177471050000071
Comparative example 1: in contrast to example 5, no citrulline was added.
Comparative example 2: in contrast to example 5, no NMN was added.
Comparative example 3: in contrast to example 5, no NMN and citrulline were added.
Anti-aging test
The caenorhabditis elegans with a large number of worm eggs in the body is cracked and then coated on an escherichia coli OP50 culture medium, the culture is carried out for 48-60 h at 20 ℃ to obtain young adults, then the synchronized nematodes are transferred to a new culture medium containing escherichia coli OP50, the young adults are divided into 9 groups, 33 nematodes in each group are cultured at 20 ℃.9 groups of culture media contained examples 2-6 and comparative examples 1-3, respectively, at a concentration of 30mg/mL, while a blank was set. The day of grouping was taken as the nematode life initiation day 0, and the nematode death was taken as the nematode life cycle. Every 24h, surviving nematodes were transferred to the same new medium and the survival of each group was recorded on day 5, 10 and 15 and the results are reported in table 2.
As can be seen from the experimental data in Table 2, the survival rates of the nematodes cultured in the culture medium containing examples 2 to 6 are higher than those of the nematodes cultured in comparative examples 1 to 3, wherein examples 4 and 5 are the most preferable examples; whereas comparative examples 1-3 have lower and lower nematode survival rates. The experiments demonstrate that the compositions of the examples of the present application have anti-aging effects.
TABLE 2 anti-aging test results
Figure RE-GDA0003177471050000081
Fatigue resistance test
The synchronized nematodes were plated on OP50 media containing 30mg/mL of examples 2-6 and comparative examples 1-3, respectively, and a blank control group was set up with 15 nematodes in each group, cultured at 20 ℃ for 24 hours, and then the nematodes were transferred to a blank medium containing M9 buffer solution, and the head swing frequency thereof was observed. Before observation, the caenorhabditis elegans swings freely for 1min, and the head swing frequency of the caenorhabditis elegans within 1min is observed and recorded under a microscope as an index of the head swing frequency. The 1 head swing is defined as its head swing direction change, which must be rotated through its body orientation direction, and the experiment is repeated three times, and the results are reported in table 3.
As can be seen from the experimental data in Table 3, the number of head swings of the nematodes after the culture in the medium containing examples 2-6 is higher than that of the nematodes after the culture in the medium containing comparative examples 1-3, wherein examples 4 and 5 are the most preferable examples; whereas the head oscillations of the nematodes of comparative examples 1-3 were less and less. Experiments show that the composition of the embodiment of the application has the effects of resisting fatigue and enhancing physiological functions.
Table 3: anti-fatigue test result
Figure RE-GDA0003177471050000091
The above description is only a preferred embodiment of the present invention, and the scope of the present invention is not limited to the above embodiment, and it will be apparent to those skilled in the art that other variations or modifications may be made on the basis of the above description. And are neither required nor exhaustive of all embodiments. Any equivalent alterations or modifications of the technical solutions and inventive concepts according to the present invention should be considered to be covered by the protection scope of the present invention.

Claims (8)

1. A composition containing NMN and citrulline comprises the following raw materials in parts by weight:
NMN: 100-300 parts;
citrulline: 1-100 parts;
l-arginine: 1-100 parts;
1-10 parts of biotin;
and 1-10 parts of magnesium glycinate.
2. The composition of claim 1, wherein: the purity of NMN is greater than or equal to 99%, the purity of citrulline is greater than or equal to 98%, the purity of L-arginine is greater than or equal to 99%, the purity of biotin is greater than or equal to 98%, and the purity of magnesium glycinate is greater than or equal to 98%.
3. The composition according to claim 1 or 2, characterized in that: the composite material is prepared from the following raw materials in parts by weight:
NMN: 120-280 parts;
citrulline: 10-90 parts;
arginine: 10-90 parts;
biotin: 2-9 parts of a solvent;
and 2-9 parts of magnesium glycinate.
4. The composition of claim 3, wherein: the composite material is prepared from the following raw materials in parts by weight:
NMN: 140-260 parts;
citrulline: 20-80 parts;
arginine: 20-80 parts;
3-8 parts of biotin;
3-8 parts of magnesium glycinate.
5. The composition of claim 4, wherein: the composite material is prepared from the following raw materials in parts by weight:
NMN: 150-250 parts;
citrulline: 30-70 parts;
arginine: 30-70 parts;
biotin: 4-6 parts;
magnesium glycinate: 4-6 parts.
6. The composition according to any one of claims 1-5, characterized in that: the composition further comprises auxiliary materials, wherein the auxiliary materials comprise at least one of the following auxiliary materials: zinc gluconate, vitamin B6, pyrro-quinoline, betaine and resistant dextrin.
7. A method for preparing a composition containing NMN and citrulline is characterized by comprising the following steps: the preparation method comprises the following steps:
s1: sieving, namely sieving all the raw materials by a sieve of 30-80 meshes, so that all the raw materials are easier to mix uniformly when being mixed;
s2: weighing, namely weighing citrulline, NMN, L-arginine, biotin and magnesium glycinate from the raw material prepared in the step S1 according to the mass parts of any one of claims 1 to 4;
s3: premixing, namely putting NMN, citrulline and L-arginine into a mixing tank, stirring and mixing to obtain a first mixed material, and putting biotin and magnesium glycinate into another mixing tank, stirring and mixing to obtain a second mixed material;
s4: mixing, namely putting the first blending material and the second blending material in the step S3 and the auxiliary material in the claim 6 into another mixing tank, and uniformly stirring to obtain a powdery mixture;
s5: and (5) subpackaging and filling, namely canning and sealing the uniform powdery mixture obtained in the step S4 in a sterile environment, and preparing powder.
8. The method of claim 7, wherein: the stirring temperature in the step S3 is 30-40 ℃.
CN202110397441.XA 2021-04-14 2021-04-14 Composition containing NMN and citrulline and preparation method thereof Pending CN113383961A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110397441.XA CN113383961A (en) 2021-04-14 2021-04-14 Composition containing NMN and citrulline and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110397441.XA CN113383961A (en) 2021-04-14 2021-04-14 Composition containing NMN and citrulline and preparation method thereof

Publications (1)

Publication Number Publication Date
CN113383961A true CN113383961A (en) 2021-09-14

Family

ID=77617741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110397441.XA Pending CN113383961A (en) 2021-04-14 2021-04-14 Composition containing NMN and citrulline and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113383961A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104814974A (en) * 2015-03-16 2015-08-05 邦泰生物工程(深圳)有限公司 Application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products
CN105852116A (en) * 2016-05-20 2016-08-17 山东明仁福瑞达制药股份有限公司 Composition having long-acting physical fatigue relieving effect and preparation method thereof
CN111642668A (en) * 2020-06-29 2020-09-11 上海圣岳生物科技有限公司 Solid beverage containing beta-nicotinamide mononucleotide and preparation method thereof
CN111838679A (en) * 2020-07-23 2020-10-30 美国营养有限公司 Novel high-efficiency nutritional dietary supplement
CN111939154A (en) * 2020-08-24 2020-11-17 周琛 Anti-aging composition, application thereof, and health food and medicine containing anti-aging composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104814974A (en) * 2015-03-16 2015-08-05 邦泰生物工程(深圳)有限公司 Application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products
CN105852116A (en) * 2016-05-20 2016-08-17 山东明仁福瑞达制药股份有限公司 Composition having long-acting physical fatigue relieving effect and preparation method thereof
CN111642668A (en) * 2020-06-29 2020-09-11 上海圣岳生物科技有限公司 Solid beverage containing beta-nicotinamide mononucleotide and preparation method thereof
CN111838679A (en) * 2020-07-23 2020-10-30 美国营养有限公司 Novel high-efficiency nutritional dietary supplement
CN111939154A (en) * 2020-08-24 2020-11-17 周琛 Anti-aging composition, application thereof, and health food and medicine containing anti-aging composition

Similar Documents

Publication Publication Date Title
CN101061860A (en) Leucine-rich nutritional compositions
CN102090692A (en) Oyster polypeptide anti-fatigue beverage and preparation method thereof
CN102793243A (en) Beverage for sub-health conditioning and its preparation method
CN111728202A (en) Food composition suitable for diabetic patients and preparation method thereof
CN105558046A (en) Formula food with special medicinal purpose and suitable for liver disease and preparation method thereof
CN105595338A (en) Food for special medical purpose applicable to diabetes and preparation method of food for special medical purpose applicable to diabetes
CN1736220A (en) Anti-fatigue yoghurt tablet
KR20240090566A (en) Yeast protein, its composition, its preparation method and application
CN106213505A (en) A kind of Moringa Haematocoocus Pluvialls tabletting health product and preparation method thereof
CN106616959A (en) Enteral nutrition preparation for patient in organ transplantation perioperative period and preparation method thereof
CN105432792A (en) Basic nutrition milk powder for preschool children, nutrition milk powder suit and preparation methods
WO2023015756A1 (en) Combined functional nutrient for cell absorption
CN113383961A (en) Composition containing NMN and citrulline and preparation method thereof
CN111642668A (en) Solid beverage containing beta-nicotinamide mononucleotide and preparation method thereof
CN101971942B (en) Nitrogen source reinforced oral liquid containing peptide and oligosaccharide and preparation method thereof
CN107712909A (en) A kind of iron zinc Muti-vitamine Oral Solution
CN113826891A (en) Composition containing compound vitamin and tabletting preparation method and application thereof
CN110584120A (en) Bone health composition
CN107773754B (en) Enteral nutrition composition for mechanically ventilated patients and preparation method thereof
CN102342400A (en) High-calcium xylitol
CN108925979A (en) A kind of diet products formula of low leucine and preparation method thereof
CN111938142A (en) Full-nutrient product and its production method
CN1364418A (en) Diary product good for brain and reproduced food
CN115868628B (en) Weight-reducing composition
CN111297821A (en) Coenzyme Q10 capsule and preparation process thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210914